Abstract
Aim:
Herbal products have been widely used, and the safety of herb-drug interactions has aroused intensive concerns. This study aimed to investigate the effects of phytochemicals on the catalytic activities of human CYP2D6*1 and CYP2D6*10 in vitro.
Methods:
HepG2 cells were stably transfected with CYP2D6*1 and CYP2D6*10 expression vectors. The metabolic kinetics of the enzymes was studied using HPLC and fluorimetry.
Results:
HepG2-CYP2D6*1 and HepG2-CYP2D6*10 cell lines were successfully constructed. Among the 63 phytochemicals screened, 6 compounds, including coptisine sulfate, bilobalide, schizandrin B, luteolin, schizandrin A and puerarin, at 100 μmol/L inhibited CYP2D6*1- and CYP2D6*10-mediated O-demethylation of a coumarin compound AMMC by more than 50%. Furthermore, the inhibition by these compounds was dose-dependent. Eadie-Hofstee plots demonstrated that these compounds competitively inhibited CYP2D6*1 and CYP2D6*10. However, their Ki values for CYP2D6*1 and CYP2D6*10 were very close, suggesting that genotype-dependent herb-drug inhibition was similar between the two variants.
Conclusion:
Six phytochemicals inhibit CYP2D6*1 and CYP2D6*10-mediated catalytic activities in a dose-dependent manner in vitro. Thus herbal products containing these phytochemicals may inhibit the in vivo metabolism of co-administered drugs whose primary route of elimination is CYP2D6.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5: 6–13.
Backlund M, Ingelman-Sundberg M . Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. Cell Signal 2005; 17: 39–48.
Thuerauf N, Lunkenheimer J . The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci 2006; 256: 287–93.
Bradford LD . CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229–43.
Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, et al. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 2000; 380: 303–8.
Fugh-Berman A, Ernst E . Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001; 52: 587–95.
Subehan, Usia T, Iwata H, Kadota S, Tezuka Y . Mechanism-based inhibition of CYP3A4 and CYP2D6 by Indonesian medicinal plants. J Ethnopharmacol 2006; 105: 449–55.
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005; 77: 415–26.
Pan Y, Abd-Rashid BA, Ismail Z, Ismail R, Mak JW, Pook PC, et al. In vitro effects of active constituents and extracts of Orthosiphon stamineus on the activities of three major human cDNA-expressed cytochrome P450 enzymes. Chem Biol Interact 2011; 190: 1–8.
Han YL, Yu HL, Li D, Meng XL, Zhou ZY, Yu Q, et al. In vitro inhibition of Huanglian [Rhizoma coptidis (L.)] and its six active alkaloids on six cytochrome P450 isoforms in human liver microsomes. Phytother Res 2011; 25: 1660–5.
Chatterjee P, Franklin MR . Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003; 31: 1391–7.
Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y . Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387–412.
Sawada M, Kamataki T . Genetically engineered cells stably expressing cytochrome P450 and their application to mutagen assays. Mutat Res 1998; 411: 19–43.
Chauret N, Dobbs B, Lackman RL, Bateman K, Nicoll-Griffith DA, Stresser DM, et al. The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes. Drug Metab Dispos 2001; 29: 1196–200.
Zhuge J, Yu YN, Wu XD . Stable expression of human cytochrome P450 2D6*10 in HepG2 cells. World J Gastroenterol 2004; 10: 234–7.
Donato MT, Jiménez N, Castell JV, Gómez-Lechón MJ . Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Dispos 2004; 32: 699–706.
Livak KJ, Schmittgen TD . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402–8.
Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD . CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 2007; 96: 2224–31.
Niwa T, Hiroi T, Tsuzuki D, Yamamoto S, Narimatsu S, Fukuda T, et al. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res 2004; 129: 117–23.
Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 2007; 35: 1292–300.
Defeudis FV . Bilobalide and neuroprotection. Pharmacol Res 2002; 46: 565–8.
Zou L, Harkey MR, Henderson GL . Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002; 71: 1579–89.
Woelkart K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, Suter A, et al. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res 2010; 24: 445–50.
Gong LL, Fang LH, Wang SB, Sun JL, Qin HL, Li XX, et al. Coptisine exert cardioprotective effect through anti-oxidative and inhibition of RhoA/Rho kinase pathway on isoproterenol-induced myocardial infarction in rats. Atherosclerosis 2012; 222: 50–8.
Pao TT, Hsu KF, Liu KT, Chang LG, Chuang CH, Sung CY . Protective action of schizandrin B on hepatic injury in mice. Chin Med J (Engl) 1977; 3: 173–9.
Liu KT, Lesca P . Pharmacological properties of dibenzo[a,c]cyclooctene derivatives isolated from Fructus Schizandrae chinensis. I. Interaction with rat liver cytochrome P-450 and inhibition of xenobiotic metabolism and mutagenicity. Chem Biol Interact 1982; 39: 301–4.
Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T . Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos 2004; 32: 1351–8.
Li WL, Xin HW, Su MW, Xiong L . Inhibitory effects of schisandrin A and schisandrin B on CYP3A activity. Methods Find Exp Clin Pharmacol 2010; 32: 163–9.
Zhang YC, Gan FF, Shelar SB, Ng KY, Chew EH . Antioxidant and Nrf2 inducing activities of luteolin, a flavonoid constituent in Ixeris sonchifolia Hance, provide neuroprotective effects against ischemia-induced cellular injury. Food Chem Toxicol 2013; 59: 272–80.
Kao TK, Ou YC, Lin SY, Pan HC, Song PJ, Raung SL, et al. Luteolin inhibits cytokine expression in endotoxin/cytokine-stimulated microglia. J Nutr Biochem 2011; 22: 612–24.
Foti RS, Wahlstrom JL, Wienkers LC . The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Dispos 2007; 35: 185–8.
Shimoi K, Okada H, Furugori M, Goda T, Takase S, Suzuki M, et al. Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett 1998; 438: 220–4.
Overstreet DH, Kralic JE, Morrow AL, Ma ZZ, Zhang YW, Lee DY . NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT2C agonists. Pharmacol Biochem Behav 2003; 75: 619–5.
Zheng J, Chen B, Jiang B, Zeng L, Tang ZR, Fan L, et al. The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo. Arch Pharm Res 2010; 33: 243–6.
Acknowledgements
This work was supported by the State Scholarship Fund from China Scholarship Council (No 201206370103), the National Natural Science Foundation of China (No 81273595, 81072706, and 84402511), the Scientific Foundation of Hunan (No 11K073 and 10JJ4020), the “863” Project (No 2012AA02A518), NCET-10-0843 and the Research Innovation Foundation of Graduate Student in Hunan province, China (CX2011B056). We are grateful to Dr Curtis D KLAASSEN and Helen RENAUD who provided language help.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary information is available at Acta Pharmacologica Sinica's website.
Supplementary information
Table S1
Primers for cDNA clone, mutation and RT-PCR (DOC 42 kb)
Rights and permissions
About this article
Cite this article
Qu, Q., Qu, J., Han, L. et al. Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6*1 and CYP2D6*10 using cell-based models in vitro. Acta Pharmacol Sin 35, 685–696 (2014). https://doi.org/10.1038/aps.2013.202
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2013.202
Keywords
This article is cited by
-
A combinatorial approach for the discovery of cytochrome P450 2D6 inhibitors from nature
Scientific Reports (2017)
-
Effects of the Chinese herbal formula “Zuojin Pill” on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype
European Journal of Clinical Pharmacology (2016)
